AstraZeneca acquires Amolyt in $1B deal
2024-03-19
AstraZeneca has bought Amolyt Pharma, including eneboparatide, a hypoparathyroidism drug, paying $800 million upfront. The deal includes an additional $250 million for regulatory milestones.
Full story:
AIChE SmartBrief
Chemical engineering news
Designed specifically for chemical engineers, AIChE SmartBrief is a FREE weekly email newsletter. It helps chemical engineers stay informed on the business and technology developments affecting our profession.
SUBSCRIBE